Lightchain Capital

Recent News

C4-logo-wht
January 04, 2024

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

READ MORE
wugen-logo-400
January 03, 2024

Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial Officer

READ MORE
C4-logo-wht
December 12, 2023

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

READ MORE
C4-logo-wht
December 12, 2023

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

READ MORE
wugen-logo-400
December 11, 2023

Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting

READ MORE
CareVet-Logo-New
December 05, 2023

CareVet Attains Mansfield Certification Plus, Demonstrating Commitment to Diversity and Inclusion

READ MORE
Logo-Geneoscopy-400
December 05, 2023

Geneoscopy and Adiso Therapeutics Announce Strategic Collaboration to Investigate New Therapeutic Options for Patients with Inflammatory Bowel Disease

READ MORE
wugen-logo-400
December 03, 2023

WUCART7 1001 Phase 1/2 Dose-Escalation/Dose-Expansion Study

READ MORE
C4-logo-wht
November 28, 2023

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

READ MORE

Contact Us

Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131

 

LinkedIn

Submit

©2024 LIGHTCHAIN CAPITAL, LLC  All Rights Reserved | Privacy Policy
Website by Tidal Media Group